PR Newswire

Kiadis Pharma Secures Manufacturing Services Agreement for its Phase II Clinical Program with Blood Cancer Treatment ATIR™ with the German Red Cross Blood Donor Service

Kiadis Pharma B.V., a clinical stage biopharmaceutical company developing treatments for blood cancers, announced today that a Services Agreement has been signed with the German Red Cross Blood Donor ...
Medindia

Kiadis Pharma Presents Positive Data from a Pre-specified Interim Analysis of the Phase II Clinical Program with its Lead Product ATIR™

ATIR™ is a cell-based product designed to enable stem cell transplantations from partially matched (haploidentical) family donors for blood cancer patients who do not have a standard of care stem cell ...
Medindia

Kiadis Pharma Provides Positive Update on its Phase II Clinical Program with Blood Cancer Treatment ATIR™

Kiadis Pharma B.V., a clinical stage biopharmaceutical company developing treatments for blood cancers, today announces the successful Phase II enrollment of approximately ten patients of whom the ...
PR Newswire

Kiadis Pharma Presents Positive Data from a Pre-specified Interim Analysis of the Phase II Clinical Program with its Lead Product ATIR™

Kiadis Pharma B.V. ("Kiadis Pharma"), a clinical stage biopharmaceutical company developing T-cell immunotherapy treatments for blood cancers, today announces positive interim data from the ongoing ...